HU-PAHT@EC2602A

Citi Maintains Buy Rating on Ping An Good Doctor

Ping An Good Doctor Becomes the First Healthcare Company to Obtain National Personal Information Protection Certification

Ping An Good Doctor Launches and Operates Travel Retirement Project

Ping An Good Doctor Stock Rises as AI Healthcare Sector Gains Market Favor

Ping An Good Doctor's Huangshan Retreat Becomes a Benchmark for Silver Tourism

Ping An Good Doctor and Wuhan No.3 Hospital Launch Direct Reimbursement Service

Ping An Good Doctor Upgrades Home-based Elder Care Services System

Ping An Good Doctor Utilizes AI Technology and Parent Integration to Offer Customized Health Management Solutions

Ping An Good Doctor Wins the Annual AI Application Breakthrough Enterprise Award

8th Shenzhen General Practice Conference Launches Healthcare Foundation Strengthening Initiative and National Family Doctor Quality Certification Project

UBS forecasts Ping An Good Doctor's CAGR at 12.7% for the next four years and resumes coverage

BOCOM International Maintains Hold Rating for Ping An Good Doctor with 15% Revenue Growth Forecast

Morgan Stanley Publishes Report on Ping An Good Doctor

Ping An Good Doctor reports 72.58% net profit growth in Q1-Q3, deepens medical insurance synergy model

Ping An Good Doctor Reports 45.7% Net Profit Growth in First 9 Months

Ping An Good Doctor Reports YTD Revenue of 3.72 Billion Yuan

PA GOODDOCTOR to Release FY2025 Q3 Earnings on October 23, Pre-Market BJT

Ping An Good Doctor Sees Positive Outlook from Morgan Stanley Post Leadership Changes

Ping An Good Doctor Shares Surge on Upgraded Ratings

Morgan Stanley Raises Ping An Good Doctor Target Price and Earnings Forecasts

BOER POWER

WAI CHUN GROUP

HUAYUEXPRESSWAY

ASIA ENERGY LOG

KNOWLEDGE ATLAS

HING LEE (HK)

JH EDUCATION

TBKS HLDGS

SIMPLICITY HLDG

01833

02318

601318

In a report released today, from Citi maintained a Buy rating on Ping An Healthcare and Technology Company, with a price target of HK$18.00.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Ping An Healthcare and Technology Company has an analyst consensus of Strong Buy, with a price target consensus of HK$19.45.

Tip Ranks

PA GOODDOCTOR

PING AN

Ping An

Citi Remains a Buy on Ping An Healthcare and Technology Company (PANHF)

512010

01099

03320

Beijing launched a pilot program for online diagnosis and treatment services on January 31, starting with three pediatric subspecialties at Beijing Children's Hospital and Capital Institute of Pediatrics. This service provides online pre-consultation, online diagnosis and treatment, and medication delivery for first-time patients, aiming to ensure the safety and quality of diagnosis and treatment. Doctors can complete the initial diagnosis and issue prescriptions via the internet

Wallstreetcn

E Fund CSI 300 Health Care ETF

SINOPHARM

CHINARES PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI All Share Health Care Devices ETF

Shanghai Pharma

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Guotai CSI Bio-medicine ETF

ALI HEALTH

JD HEALTH

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI All Share Health Care ETF

SH PHARMA

Dacheng CSI All Share Health Care Equipment and Services ETF

China Universal 800 Health Care ETF

SINOPHARM(CNCM LTD)

Ping An CSI Medicine and Medical Device Innovation ETF

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

STECH

09988

09618

The main indices of the Hong Kong stock market maintained narrow fluctuations during the trading session, with the Hang Seng TECH Index rising by 0.5% and the Hang Seng Index increasing slightly by 0.28%. There was significant sector differentiation, with the pharmaceutical retail and internet content sectors performing prominently, and ALI HEALTH soaring by 20.03% during the session. Market sentiment is characterized by a strong wait-and-see attitude, with trading activity concentrated on a few leading stocks, as funds chase after top enterprises. Current macro data changes dominate market sentiment, with investors focusing on signs of recovery in consumption and manufacturing

- The Hong Kong stock market shows moderate index performance with the Hang Seng Index at 26,973.99 points, a 0.47% increase.  
- Retail sector performance is mixed, highlighted by Alibaba's 5.38% rise amid cautious market sentiment, while pharmaceutical retail stocks like Alibaba Health surged by 20.03%.  
- Macro factors, including foreign exchange reserves and economic indicators, direct investor focus towards core assets, limiting short-term risk appetite.

Market Heartbeat

Hang Seng TECH Index

BABA-W

JD-SW

MNSO

TENCENT

SYNAGISTICS

ZONQING LTD

HAO TIAN INTL

MEITUAN

Hong Kong stocks intraday | The technology index rebounded moderately, leading pharmaceutical retail stocks surged, ALI HEALTH rose over 20%

36Kr learned that recently, PA GOODDOCTOR, in collaboration with Wuhan Third Hospital, held a launch ceremony for the "Commercial Insurance Direct Compensation" service, announcing that patients receiving treatment at the hospital can enjoy the convenient experience of "compensation upon discharge, zero upfront payment." It is understood that clients of Ping An Insurance can complete commercial insurance claims shortly after discharge settlement, without the need to fill out materials afterwards or make multiple trips between the hospital and the insurance company

36Kr

PA GOODDOCTOR "Commercial Insurance Direct Compensation" service launched

00326

02665

02589

01528

02259

09858

02255

03858

03360

CHINA STAR ENT(00326) rose 17.39%, with a trading turnover 77.7 Million HKD, and a year-to-date rose 386%. SEYOND(02665) rose 12.41%, with a trading turnover 29.9 Million HKD, and a year-to-date rose 67.6%. AUNTEA JENNY(02589) rose 9.28%, with a trading turnover 134.2 Million HKD, and a year-to-date fell 14.6%.

Top Gainers & Losers

CHINA STAR ENT

SEYOND

AUNTEA JENNY

RS MACALLINE

ZIJIN GOLD INTL

YOURAN DAIRY

HAICHANG HLDG

JIAXIN INTL RES

FE HORIZON

Top 10 HK Stock Gainers (12.15)

PA GOODDOCTOR rose 10.41%; Alibaba Health rose 2.15%, with a transaction volume of HKD 686 million; JD Health rose 1.82%, with a transaction volume of HKD 596 million; Ark Health rose 2.86%, with a transaction volume of HKD 5.22 million; Sipai Health fell 0.42%, with a market value of HKD 1.772 billion

HK Stock Movers Tracker

Hong Kong stock movement: PA GOODDOCTOR rises 10.41%, driven by upgraded elderly care services and bullish outlook from brokerages boosting stock price surge

UBS has lowered the target price for PA GOODDOCTOR from 20 yuan to 16.5 yuan, with a rating of "Neutral." The bank predicts that PA GOODDOCTOR's revenue compound annual growth rate will reach 12.7% from 2024 to 2027, and expects profit margins to improve. The adjusted net profit margin is expected to rise from 3.3% in 2024 to 9.5% in 2027, and it has raised the earnings per share forecasts for 2025 to 2027 by 216%, 55%, and 32%, respectively

AASTOCKS

UBS lowers PA GOODDOCTOR's target price to 16.5 yuan with a "Neutral" rating

Morgan Stanley released a research report stating that PA GOODDOCTOR's revenue in the first three quarters of this year increased by 13.6% year-on-year to 3.72 billion yuan (RMB), net profit increased by 72.6% year-on-year to 184 million yuan, and adjusted net profit increased by 45.7% year-on-year to 216 million yuan. Among them, revenue in the third quarter increased by 3% year-on-year, net profit in the third quarter remained roughly flat, with a net profit margin of 4.1% and an adjusted net profit margin of 4.3%. The bank currently sets a target price of HKD 16.3 and a "market perform" rating. Morgan Stanley believes the company can achieve a full-year revenue growth of over 10% and an adjusted net profit margin of 5% to 6%, which will ultimately depend on the pace of AI investment. On a positive note, the AI technology adopted by the company has improved the treatment accuracy of complex diseases to about 90%, compared to about 80% in the first half of the year, and has reduced the cost of family doctor services by approximately 52% year-on-year

Zhitong

Morgan Stanley: Expects PA GOODDOCTOR to achieve a full-year growth target of 10%, target price HKD 16.3

After announcing its performance for the first nine months, PA GOODDOCTOR's stock price once fell by more than 9%, currently reported at 14.47 yuan, down 6.52%. The company's revenue for the first three quarters increased by 13.6% year-on-year to 3.725 billion yuan, with a net profit of 184 million yuan, an increase of 72.6%. Morgan Stanley pointed out that the slowdown in growth in the third quarter was affected by deteriorating fundamentals and seasonal factors

After the earnings report, PA GOODDOCTOR faced pressure, dropping over 9% at one point

Ping An Health Medical Technology Co., Ltd. announced a 72% increase in profit for the first nine months, reaching 184 million yuan, with revenue rising 13.6% to 3.72 billion yuan. The adjusted net profit was 216 million yuan, an increase of 45.7%. The company benefited from the synergy of medical insurance models, the insurance + medical care membership model, and the advancement of corporate health management services. In the future, it will strengthen collaboration with Ping An Group to promote the digitalization and AI integration of core services. On Friday, the stock price rose by 1.7%, with a year-to-date increase of over 150%

BambooWorks

Brief: PA GOODDOCTOR's profit surged 72% in the first nine months

PA GOODDOCTOR announced its performance for the first three quarters, with total revenue of approximately 3.725 billion yuan, a year-on-year increase of 13.6%; net profit of 184 million yuan, a year-on-year increase of 72.6%. The company continues to expand its AI technology to improve the efficiency and quality of medical services, with revenue from both F-end and B-end corporate health businesses increasing by 21.5% year-on-year. As of the end of the reporting period, the number of users covered by family doctor membership rights exceeded 40 million, and the number of users benefiting from home elderly care services increased by 41% compared to last year

PA GOODDOCTOR's total revenue for the first three quarters is approximately 3.725 billion yuan, a year-on-year increase of 13.6%. It will continue to expand AI technology to enhance the efficiency and quality of medical services

PA GOODDOCTOR: Revenue for the first 9 months reached 3.72 billion yuan

PA GOODDOCTOR rose nearly 3% against the market trend, leading the sector, with the latest stock price at HKD 18.06. The company announced a new management team, with Guo Xiaotao serving as the chairman of the board and He Mingke as the CEO. Citigroup and Morgan Stanley are optimistic that the new management will strengthen the group's synergy, expecting to enhance the company's capabilities in customer and resource acquisition

Understanding the Market | PA GOODDOCTOR rose nearly 3% against the trend, leading the sector. Morgan Stanley and Citigroup both believe that the new management team will strengthen the group's synergy

On October 7th, PA GOODDOCTOR announced a management adjustment, with Li Dou resigning as Chairman of the Board and CEO, Guo Xiaotao taking over as Chairman of the Board, and He Mingke serving as CEO. This personnel change aims to maintain continuity in strategic direction and introduce talent with digital operation experience to promote business synergy and innovation. The market generally views the new team's resource integration capabilities positively, and Morgan Stanley has given PA GOODDOCTOR a "Market Perform" rating

PA GOODDOCTOR welcomes new Chairman and CEO! Morgan Stanley and Citigroup are optimistic about the group's strategic synergy and resource integration advantages

$XTALPI(02228.HK) Goldman Sachs launched the &#34;China AI Healthcare Index&#34; today, with Pharmaron as the top-weighted stock $ALI HEALTH(00241.HK)$JD HEALTH(06618.HK)$PA GOODDOCTOR(01833.HK)$YIDU TECH(02158.HK)$MircroPort Medbot-B(02252.HK)

JD HEALTH-R

Pharmaron

PHARMARON

XTALPI

HU-PAHT@EC2602A(19222.HK)

Citi Remains a Buy on Ping An Healthcare and Technology Company (PANHF)

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

Hong Kong stocks intraday | The technology index rebounded moderately, leading pharmaceutical retail stocks surged, ALI HEALTH rose over 20%

PA GOODDOCTOR "Commercial Insurance Direct Compensation" service launched

Top 10 HK Stock Gainers (12.15)